6%; subclassification unknown, 0.4%), stage III for 18.4% (stage IIIa, 9.4%; stage IIIb, 0.4%; stage IIIc, 7.6%; subclassification unknown, 1.0%), and stage IV for 7.2% (stage IVa, 0.3%; stage IVb, 6.6%; subclassification unknown, 0.3%) of all the patients. Endometrioid carcinoma was the most common, accounting for 83.1% of all the tumors. Other histological Selleckchem IWR-1 types included serous adenocarcinoma (4.6%), clear cell adenocarcinoma (2.4%), and mixed carcinoma (2.2%). Carcinosarcoma was observed in 5.0% of the patients. Of the patients, 54.4% underwent surgery alone, 38.6% received chemotherapy and other therapies, such as hormone therapy after surgery, and 1.2% received radiotherapy after surgery. ‘Other therapies’ shown in

the figure include immunotherapy. Patients aged 60–69, 50–59, and 40–49 EGFR inhibitor years accounted for 27.2%, 25.1%, and 20.0%, respectively, of all the cases, showing that the disease predominantly affected women in their 50s and 60s. Stage I accounted for 43.0% (stage Ia, 16.6%; stage Ib, 0.8%; stage

Ic, 25.6%), stage II for 8.9% (stage IIa, 0.8%; stage IIb, 0.9%; stage IIc, 7.1%), stage III for 29.3% (stage IIIa, 1.1%; stage IIIb, 3.9%; stage IIIc, 24.3%), and stage IV for 8.0% of all the patients. Neoadjuvant chemotherapy was given to 10.6% of the patients. Surface epithelial-stromal tumors accounted for 92.4%: serous adenocarcinoma accounted for 32.7%, clear cell adenocarcinoma for 23.7%, endometrioid adenocarcinoma for 16.2%, and mucinous adenocarcinoma for 11.8% of all the tumors. Sex cord-stromal and germ cell tumors were observed in 0.2% and 4.3% of the patients, respectively. Of the patients, 78.2% received chemotherapy after surgery, 19.3% underwent surgery alone, and 1.7% received chemotherapy alone. Stage I accounted for 93.0% (stage Ia, 65.0%; stage Ib, 2.3%; stage Ic, 25.7%), stage II for 1.8% (stage IIa, 0.2%; stage IIb,

0.5%; stage IIc, 1.1%), stage III for 4.5% (stage IIIa, 1.0%; stage IIIb, 1.1%; stage IIIc, 2.4%), and stage IV for 0.4% of all the Montelukast Sodium patients. Neoadjuvant chemotherapy was given to 0.4% of the patients. Mucinous tumors accounted for 59.2%, serous tumors for 21.2%, endometrioid tumors for 2.3%, and mixed tumors for 2.3% of all the tumors. In addition, granulosa cell tumors accounted for 6.5% and immature teratomas (G1, G2) for 2.9% of the tumors. Of the patients, 93.0% underwent surgery alone, and 6.9% received chemotherapy after surgery. The overall survival rates by clinical stage are shown in Figure 12. The 5-year overall survival rates were 91.3% in stage I patients (stage Ia1, 98.9%; stage Ia2, 100%; stage Ib1, 90.8%; stage Ib2, 79.0%), 77.8% in stage II patients (stage IIa, 86.7%; stage IIb, 73.9%), 56.9% in stage III patients (stage IIIa, 68.0%; stage IIIb, 56.2%), and 30.1% in stage IV patients (stage IVa, 42.7%; stage IVb, 22.7%). There were significant differences between stages I and II (P < 0.001), stages II and III (P < 0.001), and stages III and IV (P = 0.003).